EUVIMEDEUVIMED entdecken
Crossref

L26/P-786 Micronized progesterone vs desogestrel for Progesterone Primed Ovarian Stimulation (PPOS) in oocyte donation cycles: ovarian response and reproductive outcomes

M. Miguens, V. Donno, E. Clúa, I. Rodriguez, N. Polyzos

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Miguens und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does the type of progestin used in PPOS (micronized progesterone versus desogestrel) influence ovarian response parameters and reproductive outcomes in oocyte donation cycles? Summary answer PPOS regimens using micronized progesterone or desogestrel showed comparable ovarian response parameters, fertilization and blastocyst development, with no differences in clinical pregnancy rates among recipients. What is known already PPOS is an established and widely used alternative to GnRH antagonists for preventing premature LH surge during controlled ovarian stimulation. When administered during the follicular phase, progestins achieve reliable pituitary LH suppression without compromising follicular development or oocyte competence. Several publications have consistently shown ovarian response and reproductive outcomes comparable in PPOS cycles to those achieved with antagonist protocols. Although both micronized progesterone and desogestrel are currently used in donor cycles, direct comparative data between these progestins remain limited. Study design, size, duration A retrospective single-centre study was conducted at a university-affiliated fertility centre, including 769 oocyte donation cycles performed between January 2022 and October 2025. Ovarian stimulation was performed with rFSH (225-300 IU), in PPOS protocol for LH suppression with desogestrel 75 µg daily or micronized progesterone 200 mg daily, administered from the first day of ovarian stimulation until ovulation triggering with a gonadotropin-releasing hormone agonist (GnRH-a; triptorelin 0.2 mg). Participants/materials, setting, methods Donors aged 18-35 years with regular cycles, BMI 18-28 kg/m2 and no relevant history underwent PPOS using oral desogestrel (n = 546) or micronized progesterone (n = 223), resulting in 1649 recipients and 1707 cryotransfers. Ovarian response, clinical pregnancy rates in recipients were compared between groups, with clinical pregnancy rate as primary outcome. Categorical variables were analized using the chi-square test or Fisher’s test, continuous variables with Student’s t-test, and treatment effect was assessed using linear and logistic regression. Main results and the role of chance Donor baseline characteristics were comparable between groups, although donors in the desogestrel group were younger than those receiving micronized progesterone (27.21 ± 4.57 vs. 28.73 ± 4.43 years; p < 0.001). Regarding stimulation, the total gonadotrophin dose was slightly lower in the desogestrel group (1688.23 ± 840.14 vs 1889.79± 898.11; p = 0.004) while stimulation duration was similar (12.01±25.31 vs. 11.79±23.96; p > 0.05). No significant differences were observed in retrieved oocytes (MD -0.8, 95% CI -2.2 to 0.6) or MII oocytes (MD -0.6, 95% CI -1.8 to 0.5), nor in cancellation rates. Mean LH levels on trigger day were significantly lower in the desogestrel group compared with micronized progesterone (1.13 ± 1.20 vs 3.07 ± 2.59 IU/L; p < 0.05), with no difference in premature LH surge rates (0.4% 95% CI 0.01-2.4 vs 1.3% 95% CI 0.15-4.5, respectively; p = 0.369). Laboratory outcomes from 1649 recipient cycles showed similar fertilization rates between desogestrel cycles (80.5%, 95% CI 79.3 – 81.7) and micronized progesterone cycles (79.4%, 95% CI 77.6 – 81.2), as well as blastocyst development rates (43.7 %, 95% CI 42.1-45.3 vs 46.6%, 95% CI 44.3-48.8, respectively). Clinical pregnancy rates did not differ between groups (52.7% desogestrel group vs 49.7% micronized progesterone group; p > 0.05) Limitations, reasons for caution The interpretation of the findings of this study is limited by the retrospective nature of the analysis and the potential for unmeasured confounding. In addition, data derive from a single center, which may limit generalizability to other clinical settings. Wider implications of the findings These findings support the use of either micronized progesterone or desogestrel in PPOS oocyte donation cycles, with comparable ovarian response, laboratory outcomes, and pregnancy rates. This flexibility may help to individualize stimulation protocols without compromising reproductive outcomes. Trial registration number No

Zitieren

APA

Miguens, M., Donno, V., Clúa, E., Rodriguez, I., & Polyzos, N. (2026). L26/P-786 Micronized progesterone vs desogestrel for Progesterone Primed Ovarian Stimulation (PPOS) in oocyte donation cycles: ovarian response and reproductive outcomes. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1113

Vancouver

Miguens M, Donno V, Clúa E, Rodriguez I, Polyzos N. L26/P-786 Micronized progesterone vs desogestrel for Progesterone Primed Ovarian Stimulation (PPOS) in oocyte donation cycles: ovarian response and reproductive outcomes. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1113

BibTeX
@article{Miguens2026,
  author = {Miguens, M. and Donno, V. and Clúa, E. and Rodriguez, I. and Polyzos, N.},
  title = {L26/P-786 Micronized progesterone vs desogestrel for Progesterone Primed Ovarian Stimulation (PPOS) in oocyte donation cycles: ovarian response and reproductive outcomes},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1113}
}
Kostenlos starten →